Elsevier's MEDalternatives Offers Additional Cost Saving Options for Payers and Members

 Elsevier's MEDalternatives Offers Additional Cost Saving Options for Payers
                                 and Members

  PR Newswire

  TAMPA, Florida, February 6, 2013

TAMPA, Florida, February 6, 2013 /PRNewswire/ --

  New comprehensive resource for drug therapy options and costs helps health
  plan payers and members save on drug spend with information on alternative

Elsevier's Gold Standard , a leading drug information provider, today
announced the launch of the MEDalternatives ™ database, a comprehensive
resource for drug therapy options designed to give health plans and their
members additional drug cost savings options through access to information on
alternative therapies. MEDalternatives uses only evidence-based alternatives
that have comparable or better efficacy and safety, compared to current

MEDalternatives covers a broad range of health conditions and the widest scope
of medications, including a complete offering of drugs, drug classes, and
product formulations. It returns alternatives within the class of the
patient's current medication and across classes, including both generics and
brands, and also provides therapeutically appropriate choices among subclasses
of drugs.

MEDalternatives includes complete dosing options to ensure accurate
comparisons in daily/weekly regimens and monthly/yearly costs, including those
for in-store purchase versus mail-order delivery.

"MEDalternatives delivers a unique payer solution that identifies safe and
cost- effective medication alternatives for achieving therapy compliance and
prescription cost savings," said Marianne Messer, President, Elsevier's Gold
Standard. "This will help our payer and PBM clients reduce prescription drug
costs, particularly those who have already maximized their brand-to-generic
switching, and improve medication adherence."

MEDalternatives helps:

  *Simplify drug regimens and drive down costs for payers and patients
  *Improve compliance for healthier and less expensive outcomes
  *Payers control prescription costs by offering therapeutic alternatives on
    brand-to-brand drugs, as well as brand-to-generic drugs
  *Payers educate providers and members on where savings can be attained on
  *PBMs (Pharmacy Benefit Managers) enforce formulary compliance
  *Help providers identify alternative therapies to reduce costs
  *Guide consumers toward more affordable, safer and more effective
    medication options
  *Involve consumers in these choices, knowing that cost and convenience play
    a central role in adherence to treatment
  *Prepare consumers to discuss options with their healthcare providers
  *Boost patients' satisfaction with their drug benefits

MEDalternatives is derived from the most technologically sophisticated drug
database available today and will easily integrate within and across diverse
healthcare systems.

For more information about Elsevier's Gold Standard and MEDalternatives, visit
http://www.goldstandard.com/medalternatives .

Elsevier's Gold Standard

Based in Tampa, FL, Elsevier's Gold Standard uses innovative technologies to
provide a complete suite of drug information and decision support solutions.
With a tenacious commitment to product quality, Elsevier's Gold Standard
solutions empower healthcare organizations, professionals and consumers to
meet the most pressing healthcare challenges, improve patient safety and
ensure optimal outcomes. To learn more about Elsevier's Gold Standard, visit
http://www.goldstandard.com .

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet and Cell , and close to 20,000 book titles, including
major reference works from Mosby and Saunders. Elsevier's online solutions
include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Nursing
Suite , which enhance the productivity of science and health professionals,
and the SciVal suite and MEDai's Pinpoint Review , which help research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC , a world-leading
provider of professional information solutions in the Science, Medical, Legal
and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and
Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London
Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact Christopher Capot Director, Corporate Relations Elsevier
+1-212-633-3164 c.capot@elsevier.com
Press spacebar to pause and continue. Press esc to stop.